Fiera Capital Corp Has $40.17 Million Stock Holdings in Insmed Incorporated (NASDAQ:INSM)

Fiera Capital Corp lowered its position in Insmed Incorporated (NASDAQ:INSM - Free Report) by 1.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 581,854 shares of the biopharmaceutical company's stock after selling 10,561 shares during the quarter. Fiera Capital Corp owned 0.33% of Insmed worth $40,171,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in INSM. Jennison Associates LLC increased its position in shares of Insmed by 0.6% during the fourth quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company's stock worth $53,424,000 after acquiring an additional 4,560 shares during the last quarter. Capital CS Group LLC acquired a new position in shares of Insmed during the fourth quarter worth approximately $586,000. Orion Portfolio Solutions LLC lifted its position in Insmed by 48.5% in the third quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company's stock worth $2,050,000 after purchasing an additional 9,170 shares during the period. Ally Bridge Group NY LLC lifted its position in Insmed by 16.9% in the third quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company's stock worth $11,011,000 after purchasing an additional 21,833 shares during the period. Finally, TimesSquare Capital Management LLC acquired a new stake in Insmed in the third quarter worth approximately $35,322,000.

Insider Activity

In other news, CEO William Lewis sold 18,750 shares of Insmed stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $69.91, for a total transaction of $1,310,812.50. Following the completion of the sale, the chief executive officer now owns 384,960 shares of the company's stock, valued at approximately $26,912,553.60. This trade represents a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the firm's stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $80.00, for a total value of $7,291,200.00. Following the completion of the transaction, the insider now owns 97,083 shares in the company, valued at $7,766,640. The trade was a 48.42 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 495,135 shares of company stock valued at $38,409,713. 4.60% of the stock is owned by insiders.

Insmed Stock Up 0.8 %

Shares of INSM traded up $0.64 during mid-day trading on Monday, hitting $79.31. 1,167,289 shares of the company's stock were exchanged, compared to its average volume of 1,950,375. The company has a market cap of $14.19 billion, a PE ratio of -14.29 and a beta of 1.11. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $82.04. The company has a 50-day simple moving average of $73.51 and a 200 day simple moving average of $73.31.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on INSM shares. JPMorgan Chase & Co. increased their price objective on Insmed from $83.00 to $92.00 and gave the company an "overweight" rating in a research report on Friday, February 7th. HC Wainwright reaffirmed a "buy" rating and issued a $90.00 price target on shares of Insmed in a research note on Friday, November 1st. Truist Financial reissued a "buy" rating and set a $105.00 target price (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. Morgan Stanley upped their price target on shares of Insmed from $85.00 to $90.00 and gave the company an "overweight" rating in a report on Thursday, February 6th. Finally, Stifel Nicolaus increased their target price on shares of Insmed from $88.00 to $97.00 and gave the company a "buy" rating in a research note on Tuesday, February 11th. One research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $88.71.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.